In bladder cancer, IGF2BP1 directly stabilizes PKM2 mRNA, while circFAM13B competes for IGF2BP1 binding, leading to PKM2 destabilization, reduced glycolysis, and improved sensitivity to immunotherapy34. The gene discussed is IGF2BP1; the disease is urinary bladder cancer.